FindTrial
Sign In

Iparomlimab/Tuvonralimab

DRUG5 trials

Sponsors

Shanghai Gynecologic Oncology Group, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Soochow University, Sun Yat-sen University

Conditions

Beta BlockerColon Cancer (Stage II &Amp; III)Colorectal NeoplasmsEpithelial Ovarian CancerFallopian Tube CancerImmunotherapyLOCALLY ADVANCED CERVICAL CANCERSNeoadjuvant Chemoimmunotherapy

Phase 1

Surgery for Relapsed Ovarian Cancer in Precision
Not yet recruitingNCT06602063
Shanghai Gynecologic Oncology GroupEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Start: 2025-07-31End: 2030-06-30Target: 33Updated: 2025-06-27

Phase 2

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Not yet recruitingNCT07007728
Peking University Cancer Hospital & InstituteColorectal Neoplasms, Secondary Malignant Neoplasm of Liver
Start: 2025-06-01End: 2026-12-31Target: 54Updated: 2025-06-06
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
RecruitingNCT07232654
Cancer Institute and Hospital, Chinese Academy of Medical SciencesLOCALLY ADVANCED CERVICAL CANCERS
Start: 2025-11-11End: 2028-02-28Target: 30Updated: 2025-12-01
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
Not yet recruitingNCT07454018
The First Affiliated Hospital of Soochow UniversityPlatinum-sensitive Ovarian Cancer, Recurrent Ovarian Cancer
Start: 2026-03-01End: 2029-12-31Target: 45Updated: 2026-03-06
Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study
Not yet recruitingNCT07549906
Sun Yat-sen UniversityBeta Blocker, Colon Cancer (Stage II &Amp; III), Immunotherapy +1
Start: 2026-04-20End: 2026-12-31Target: 45Updated: 2026-04-24